Bank of America Cuts LENZ Therapeutics (NASDAQ:LENZ) Price Target to $29.00

LENZ Therapeutics (NASDAQ:LENZ) had its target price cut by Bank of America from $35.00 to $29.00 in a research report released on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

LENZ has been the topic of a number of other reports. HC Wainwright reiterated a “buy” rating on shares of LENZ Therapeutics in a research report on Monday, December 15th. Wall Street Zen downgraded shares of LENZ Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. William Blair reiterated an “outperform” rating on shares of LENZ Therapeutics in a report on Tuesday, March 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of LENZ Therapeutics in a research report on Thursday, January 22nd. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $45.60.

LENZ Therapeutics Stock Down 6.0%

Shares of LENZ opened at $8.40 on Wednesday. The stock’s fifty day simple moving average is $13.75 and its 200-day simple moving average is $24.08. The firm has a market capitalization of $263.34 million, a PE ratio of -2.99 and a beta of 0.52. LENZ Therapeutics has a 12-month low of $8.40 and a 12-month high of $50.40.

LENZ Therapeutics (NASDAQ:LENZ) last announced its quarterly earnings data on Tuesday, March 24th. The company reported ($1.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.25). The company had revenue of $1.59 million during the quarter, compared to analysts’ expectations of $3.09 million. Analysts anticipate that LENZ Therapeutics will post -2.18 EPS for the current year.

Hedge Funds Weigh In On LENZ Therapeutics

Several institutional investors have recently modified their holdings of LENZ. Skandinaviska Enskilda Banken AB publ increased its stake in LENZ Therapeutics by 99.0% during the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 185,642 shares of the company’s stock worth $8,647,000 after purchasing an additional 92,362 shares in the last quarter. Versant Venture Management LLC bought a new position in LENZ Therapeutics in the third quarter valued at approximately $123,758,000. First Light Asset Management LLC acquired a new position in shares of LENZ Therapeutics in the third quarter valued at approximately $32,282,000. Sovran Advisors LLC boosted its holdings in shares of LENZ Therapeutics by 164.5% in the third quarter. Sovran Advisors LLC now owns 106,920 shares of the company’s stock valued at $4,980,000 after buying an additional 66,497 shares during the period. Finally, Tyro Capital Management LLC bought a new stake in shares of LENZ Therapeutics during the third quarter worth $4,689,000. Institutional investors own 54.32% of the company’s stock.

LENZ Therapeutics News Summary

Here are the key news stories impacting LENZ Therapeutics this week:

• Positive Sentiment: HC Wainwright raised near-term EPS forecasts for Q1 and Q2 2026 and upgraded FY2026/2027 trajectory (estimates moved closer to break-even), signaling improving visibility on operating performance. (Source: HC Wainwright research note)
• Positive Sentiment: HC Wainwright published a long‑term bullish projection (FY2030 EPS of $3.18), reflecting confidence in LENZ’s longer‑term commercialization or pipeline upside. (Source: HC Wainwright research note)
• Positive Sentiment: Bank of America set a new $29 price target for LENZ, which implies meaningful upside from current levels and may support buy-side interest. LENZ Therapeutics (NASDAQ:LENZ) Given New $29.00 Price Target at Bank of America
• Neutral Sentiment: Recent earnings call materials and coverage are available for review — useful for investors digging into guidance, R&D progress and management comments. Q4 2025 Earnings Call Summary Q4 2025 Earnings Call Transcript Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: HC Wainwright trimmed its Q4 2026 EPS estimate (from -$0.41 to -$0.48) and reduced several multi‑year forecasts (FY2028 and FY2029 down), which increases near‑term earnings uncertainty. (Source: HC Wainwright research notes)
• Negative Sentiment: LENZ reported a Q4 2025 earnings miss (EPS and revenue below consensus), a direct catalyst that likely pressured the stock and prompted analyst revisions. Q4 2025 Earnings Call Summary
• Negative Sentiment: Citigroup cut its price target sharply (from $52 to $26) despite keeping a buy rating — the lower PT reduces near‑term upside expectations from some institutional investors. Citigroup Lowers LENZ Price Target

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.